Investors

Investor Facts

Our diversified, multi-industry revenue base, vigorous pursuit of aftermarket business, and successful pursuit and integration of acquisitions provides top line and bottom line growth for the company and our shareholders.

Our market diversification began fifty years ago, and our international diversification began more than thirty-five years ago. Just as investors balance their portfolios of stocks, so do we balance our portfolio of businesses to benefit both the company and its shareholders.

Review our most recent SEC filings including 8-K and 10-Q documents.      

Printable Investor Fact Sheet

 

Historical Revenue Earnings and EPS

Year Revenue Net Earnings EPS  
2006 $1,306 $81 $1.97  
2007 $1,558 $101 $2.34  
2008 $1,903 $119 $2.75  
2009 $1,849 $85 $1.98  
2010 $2,114 $108 $2.36  
2011 $2,331 $136 $2.95  
2012 $2,470 $152 $3.33    
2013b $2,610 $120 $2.63    
2014Ea $2,672 $169 $3.65  

Dollars in Millions, except EPS

aSales for 2014 are forecast $2.67 billion, net earnings of $169 million and EPS of $3.65.
bThe Company announced fiscal year 2013 sales of $2.61 billion, up 6%. Net earnings of $120 million and EPS of $2.63. Fiscal ’13 included a $.52 goodwill impairment charge in Medical Devices in the fourth quarter, $.15 of asset write-downs in the third quarter and $.20 of restructuring during the year. Exclusive of those charges, adjusted net earnings of $161 million and adjusted earnings per share of $3.50 were up 5% from a year ago. The results are described in an 
8-K filed on 11/01/2013. 

 As of 1/24/2014

Recent Financial Performance

Recent Quarterly Results Q1 '14* Q1 '13
Net Sales $643 $621
Net Earnings $32.1  $34.1
Diluted EPS $.70 $.75
Shares Outstanding+ 46.0 45.7

Note: Results in Q1 FY14 included a charge of $.12 per share for costs associated with the previously announced redemption of high yield notes and a $.06 per share investment write down. Exclusive of those charges, adjusted earnings per share of $.88 were up 17% from a year ago.  

Dollars in Millions, except EPS 
Q1 FY'14 results are described in an 8-K filed on 1/24/2014.
+Shares outstanding include dilutive effects of equity awards

 

Sales ($ Billions)

      As of  01/24/2014

Net Income ($ Millions)

  

     As of  01/24/2014

Earnings per Share ($)

Note: Results in Q1 FY14 were described in an 8-K filed on 1/24/2014.

Dollars in Millions, except EPS 
Q1 FY'14 and FY 2014E forecast were reported 1/24/14
+Shares outstanding include dilutive effects of equity awards

 

 

Balanced Revenues

 

Cautionary

This page contains forward-looking financial information. By nature, such forward-looking information involves risks and uncertainties because they relate to events and depend on circumstances that will or may occur in the future. Actual results may differ from those expressed in such statements. The forward-looking statements included on this page are only made as of the date shown, and the Company disclaims any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Review our most recent SEC filings including 8-K and 10-Q documents.

01/24/2014

Highlights

Founded in 1951
Traded NYSE: MOGA and MOGB
Fiscal Year End 2013: September 27, 2014
Employees Worldwide: 11,150+/-

Key Military and Commercial Programs:

F-35 Joint Strike Fighter, F15, F/A-18E/F, F-16
F-15 Japan
Indian Light Combat Aircraft
H-60 Black Hawk, SH-60 Seahawk
V-22 Osprey
Boeing KC-46 Tanker
Boeing 737, 747, 757, 767, 777, 787
Airbus A320, A330, A340, A350
COMAC C919
Embraer E-Jet E2
Mars Curiosity Rover, Galileo, LADEE
NASA Space Launch Vehicle & Orion
Hellfire, TOW, MALD, Trident D-5
Maverick, Tactical Tomahawk
Delta IV, Atlas V, Antares
Guardian Missile Defense System
MTS (Multi Spectral Targeting System)
EQ-36, CH-47, SNIPER
U.S Marine Corps Light Armored Vehicle (LAV)
Bradley, Abrams
Virginia Class Submarine

 

FY 2014E Segment Sales

Analyst Coverage - Year Initiated

> Cai von Rumhor, Cowen and Company – 1998
> Ron Epstein, Bank of America/ML – 1999
> J.B. Groh & Chris Denny, DA Davidson  – 2004
> Rob Stallard & Steven Cahall, RBC Capital Markets – 2007
> Tyler Hojo, Sidotti & Company – 2008
> Mike Ciarmoli, KeyBanc Capital Markets – 2009
> Julie Yates Stewart, Credit Suisse – 2011